Persistence Pays Off For Amicus: Positive Migalastat Data In Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Amicus will return to FDA with positive data on its oral small molecule chaperone migalastat in Fabry patients after a Phase III trial showed the oral drug had comparable efficacy to existing enzyme replacement therapies.